German Centre for Infection Research HIV Translational Platform

ConditionHIV
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital of Cologne

About this trial

Despite major advances in therapy and management, HIV/AIDS continues to be a major cause of infectious disease morbidity and mortality on a global scale. The discovery of effective antiretroviral treatment has turned HIV infection into a manageable chronic disease in most patients with access to care. However, the different economic and epidemiologic situation in developing and developed countries requires different research priorities, so that three main challanges are universal and in focus of research of the DZIF HIV Translational Platform:

* Prevention of HIV infection * Long-term life with HIV * HIV cure

The "Translation Reserach HIV" will bring together clinical researchers in HIV infection in order to develop new treatment options to the above mentioned main challanges. It will take advantage of existing expertise (e.g. basic science, novel targets for treatment and HIV eradiation) of the partner sites. This platform is necessary because Germany's HIV research has suffered in the past from a lack of integration between its excellent basic science and clinical research. In addition, there was too little integration into networks that address the main international challenges. There is an urgent need to link these research strands through dedicated structures emphasising the translation of preclinical results into new therapies.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

HIV positive

Disqualifiers

None

Trial population

Patients HIV positive and who are treated in one of the six partner sites

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

10,000 Participants
are grouped into 9 trial groups

9

Trial groups

See each trial group below.

Group A: Site Bonn
Group B: Site Heidelberg
Group C: Site Munich
Group D: Site Hamburg
Group E: Site Hannover
Group F: Site Cologne
Group G: Site Freiburg
Group H: Site Frankfurt
Group I: Site Essen

Trial outcomes

Primary outcomes

1

Incidence of new HIV infections in Germany

Overall long-term goal of the platform is to develop a translation strategy for the preclinical results concerning HIV prevention from all German research groups with outstanding expertise. Specific outcome measures will be detailed in future subprojects.

Time frame
Up to 20 years

Secondary outcomes

1

Incidence of chronic organ failure and malignant diseases in HIV infected patients

Overall long-term goal of this platform is to focus on co-infections, organ damage and malignant diseases. Research on identifying new correlates of protection and long term viral control will contribute to improved management of HIV infection. Specific outcome measures will be detailed in future subprojects.

Time frame
Up to 20 years

Other outcomes

1

Sustained viral response rate 12 months after discontinuation of ART

Overall long-term goal of this platform is to eliminate silently infected cells or the HIV genomes integrated in these cells. These approaches are currently mostly at the stage of basic research or early preclinical development and need to be developed in the translational chain. Specific outcome measures will be detailed in future subprojects.

Time frame
Up to 20 years

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital of Cologne

Lead sponsor

German Center for Infection Research

Collaborator

German Federal Ministry of Education and Research

Collaborator